Dapagliflozin for the treatment of Type 2 diabetes

References

• International Diabetes Federation. Diabetes prevalence. Available from: www.idf.org/diabetesatlas/5e/the-global-burden [Last accessed 6 November 2013]
   Google Scholar
• Klein R, Klein BEK. Vision disorders in diabetes. In: Diabetes in America. 2nd edition. National Diabetes Data Group, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda, MD, USA: 1995. p. 293-338
   Google Scholar
• Warram JH, Gearin G, Laffel L, et al. Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. J Am Soc Nephrol 1996;7:930-7
   PubMed Web of Science ®Google Scholar
• Reenders K, de Nobel E, van den Hoogen HJ, et al. Diabetes and its long-term complications in general practice: a survey in a well-defined population. Fam Pract 1993;10:169-72
   PubMed Web of Science ®Google Scholar
• Lee WL, Cheung AM, Cape D, et al. Impact of diabetes on coronary artery disease in women and men: a meta-analysis of prospective studies. Diabetes Care 2000;23:962-8
   PubMed Web of Science ®Google Scholar
• Booth GL, Kapral MK, Fung K, et al. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 2006;368:29-36
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
   PubMed Web of Science ®Google Scholar
• Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-17
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients withType 1 diabetes. N Engl J Med 2005;353:2643-53
   PubMed Web of Science ®Google Scholar
• Holman RR, Rahman T, Ismail AA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
   PubMed Web of Science ®Google Scholar
• Ray KR, Seshasai SRK, Sivakumaran R, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomized controlled trials. Lancet 2009;373:1765-2
   PubMed Web of Science ®Google Scholar
• Harris M. Health care and health status and outcomes for patients with type 2 diabetes. Diabetes Care 2000;23:754-8
   PubMed Web of Science ®Google Scholar
• Silverman M. Structure and function of hexose transporters. Annu Rev Biochem 1991;60:757-94
   PubMed Web of Science ®Google Scholar
• Wright EM. Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol 2001;280(1):F10-18
   PubMed Web of Science ®Google Scholar
• Thomson AB, Wild G. Adaptation of intestinal nutrient transport in health and disease. Dig Dis Sci 1997;42(3):453-88
   Google Scholar
• Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev 2011;91:733-94
   PubMed Web of Science ®Google Scholar
• Vallon V, Platt KA, Cunard R, et al. SGLT mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 2011;22:104-12
   PubMed Web of Science ®Google Scholar
• Francis J, Zhang J, Farhi A, et al. A novel SGLT2 mutation in a patient with autosomal recessive renal glucosuria. Nephrol Dial Transplant 2004;19:2394-6
   PubMed Web of Science ®Google Scholar
• Scholl-Burgi S, Santer R, Ehrich JH. Long-term outcome of renal glucosuria type O: the original patient and his natural history. Nephrol Dial Transplant 2004;19:2394-6
   PubMed Web of Science ®Google Scholar
• Oemar BS, Byrd DJ Brohehl J. Complete absence of tubular glucose reabsorption: a new type of renal glucosuria (type 0). Clin Nephrol 1987;27:156-60
   PubMed Web of Science ®Google Scholar
• Dexjeux JF, Turk E, Wright E. Congenital selective Na/D-glucose cotransport defects leading to renal glucosuria, congenital selective intestinal malabsorption of glucose, galactose. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic basis of inherited disease. 7th edition. McGraw-Hill; NY, USA: 1994. p. 3563-80
   Google Scholar
• van den Heuvel LP, Assink K, Willemsen M, et al. Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2). Hum Genet 2002;111:544-7
   PubMed Web of Science ®Google Scholar
• Calado J, Loeffler J, Sakallioglu O, et al. Familial renal glucosuria: SLC5A2 mutation analysis and evidence of salt-wasting. Kidney Int 2006;69:852-5
   PubMed Web of Science ®Google Scholar
• Ehrenkranz JRL, Lewis NG, Kahn CR. Phlorizin: a review. Diabetes Metab Res Rev 2005;21:31-8
   PubMed Web of Science ®Google Scholar
• Keller DM, Lotspeich WD. Effect of phlorizin on the osmotic behaviour of mitochondira in isotonic sucrose. J Biol Chem 1959;234:991-4
   PubMed Web of Science ®Google Scholar
• Alvarado FC, Crane RK. Phlorizin as a competitive inhibitor of the active transport of sugars by hamster small intestine in vitro. Biochim Biophys Acta 1962;56:170-2
   PubMedGoogle Scholar
• Han S, Hagan DL, Taylor JR, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008;57:1723-9
   PubMed Web of Science ®Google Scholar
• Meng W, Ellsworth BA, Nirschi AA, et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008;51:1145-9
   PubMed Web of Science ®Google Scholar
• Komoroski B, Vachharajani N, Feng Y, et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol 2009;85(5):513-19
   Google Scholar
• Hummel CS, Lu C, Liu J, et al. Structural selectivity of human SGLT inhibitors. Am J Physiol Cell Physiol 2012;302(2):C373-82
   PubMed Web of Science ®Google Scholar
• Obermeier MT, Yao M, Khanna A, et al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II (SGLT2) inhibitor, in animals and humans. Drug Metab Dispos 2010;38(3):405-14
   PubMed Web of Science ®Google Scholar
• Macdonald FR, Peel JE, Jones HB, et al. The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diabetes Obes Metab 2010;12(11):1004-12
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Ramos SJ, Salsali A, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Care 2010;33(10):2217-24
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010;375(9733):2223-33
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Gross JL, Hennicken D, et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo controlled 102-week trial. BMC Med 2013;11:1
   Google Scholar
• Nauck MA, Del Prato S, Meier J, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled non-inferiority trial. Diabetes Care 2011;34(9):2015-22
   PubMed Web of Science ®Google Scholar
• Del Prato S, Nauck MA, Durán-Garcia S, et al. Durability of dapagliflozin vs. glipizide as add-on therapies in T2DM inadequately controlled on metformin: 4-year data. American Diabetes Association; 21 – 25 June 2013; Chicago, IL, USA
   Google Scholar
• Strojek K, Yoon K, Hruba V, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 2011;13(10):928-38
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Vico M, Wei L, et al. Effects of dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, on hemoglobin A1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012;35(7):1473-8
   PubMed Web of Science ®Google Scholar
• Jabbour SA, Hardy E, Sugg J, et al. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care 2014;37:740-50
   PubMed Web of Science ®Google Scholar
• Wilding JP, Woo V, Soler NG, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: a randomized, controlled trial. Ann Intern Med 2012;156(6):405-15
   PubMed Web of Science ®Google Scholar
• Wilding J, Woo V, Rohwedder K, et al. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over two years. Diabetes Obes Metab 2013. [Epub ahead of print]
   Google Scholar
• Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012;97(3):1020-31
   PubMed Web of Science ®Google Scholar
• Bolinder J, Ljunggren O, Johansson L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab 2014. [Epub ahead of print]
   Google Scholar
• US FDA. Available from: www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm252891.htm
   Google Scholar
• Baker WL, et al. Effects of sodium glucose co-transporter 2 on blood pressure: A review and meta-analysis. J Am Soc Hyperten 2014;8(4):262-75
   PubMed Web of Science ®Google Scholar
• Woo V, Langkilde AM, Sugg J, Parikh S. Dapagliflozin, a novel antihyperglycemic agent that promotes urinary glucose excretion, reduces systolic blood pressure in patients with type 2 diabetes mellitus. Circulation 2011;124:A9520
   Google Scholar
• Leiter LA, Cefalu WT, de Bruin T, et al. Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. J Am Geriatr Soc 2014;62(7):1252-62
   PubMed Web of Science ®Google Scholar
• Cefalu WT, Gause-Nilsson I, deBruin TW, et al. Long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes, cardiovascular disease and hypertension. abstract Am Diabetes Assoc 2014; In press
   Google Scholar
• Langkilde AM, Johansson P, Ptaszynska A, Johnsson E. Cardiovascular safety of the SGLT2 inhibitor dapagliflozin: meta-analysis with >6000 patient-years exposure. Circulation 2013;128(Suppl 22):A11105
   Google Scholar
• Multicenter trial to evaluate the effect of dapagliflozin on the incidence of cardiovascular events. Available from: https://clinicaltrials.gov/ct2/show/NCT01730534?term=dapagliflozin%2C+cardiovascular&rank=1
   Google Scholar
• Johnsson KM, Ptaszynska A, Schmitz B, et al. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications 2013;27(5):473-9
   PubMed Web of Science ®Google Scholar
• Johnsson KM, Ptaszynska A, Schmitz B, et al. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications 2013;27(5):479-84
   PubMed Web of Science ®Google Scholar
• US FDA. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM378076.pd
   Google Scholar
• Henry RR, Rosenstock J, Chalamandaris AG, et al. Exploring the potential of dapagliflozin in Type 1 diabetes: phase 2a pilot study. abstract 70-LB American Diabetes Association; Chicago, IL, USA; 2013
   Google Scholar
• Matthaei S, et al. EASD Annual Meeting 2013. Abstract 937
   Google Scholar